Molbio Diagnostics Limited
(Formerly Molbio Diagnostics Private Limited)
Plot No. L - 46, Phase II D, Verna Industrial Estate
Verna, Goa - 403722, India
+91 832 6724888 www.molbiodiagnostics.com

7th September 2026

To,

BSE Limited ('BSE')
Listing Department
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
2nd Floor, Dalal Street
Mumbai – 400 001
BSE Script Code: 544866

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex
Bandra (E), Mumbai — 400 051
Symbol: MOLBIO

Subject: Press Release on Unaudited Financial Results for the quarter ended June 30, 2026

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in terms of other applicable laws, if any, please find enclosed the Press Release on Unaudited Financial Results for the quarter ended June 30, 2026.

This intimation is also available on the Company's website at www.molbiodiagnostics.com in compliance with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information, records and appropriate dissemination.

Thanking you.

For and on behalf of Molbio Diagnostics Limited

DARSHAN RAGHUNATH KAREKAR
Digitally signed by DARSHAN RAGHUNATH KAREKAR
Date: 2026.09.07 09:24:35 +05'30'

Darshan Raghunath Karekar
Company Secretary & Compliance Officer
M. No: F13569
Place: Verna-Goa

EARNINGS PRESS RELEASE

Molbio Diagnostics reports Q1 FY27 performance, with continued momentum in Truenat test-kit volume

- Total Income stood at ₹411.48 Cr
- EBITDA at ₹103.68 Cr against a loss of ₹14.50 Cr in Q1 FY26; EBITDA Margin at 25.20%
- PAT at ₹ 52.74 Cr against a loss of ₹23.94 Cr in Q1 FY26; PAT Margin at 12.82%

Goa, India, 7th September 2026: Molbio Diagnostics Limited (NSE: MOLBIO; BSE: 544866), an innovative point-of-care diagnostics company, announced its financial results for the quarter ended June 30, 2026, following the Company's listing on August 17, 2026.

Consolidated Financial Highlights

(In ₹ Crore)

Particulars	Q1 FY27	Q1 FY26	Q4 FY26
Total Income*	411.48	100.47	565.41
EBITDA*	**103.68**	**(14.50)**	**163.51**
EBITDA Margin (%)	*25.20%*	*(14.43%)*	*28.92%*
PAT	**52.74**	**(23.94)**	**95.83**
PAT Margin (%)	*12.82%*	*(23.83%)*	*16.95%*

**Total Income & EBITDA includes other income*

Key Financial & Operational Highlights

- Q1 FY27 Total Income stood at ₹411.48 Cr as against ₹100.47 Cr in Q1 FY26, driven by continued volume of Truenat test-kit consumption
- Q1 FY27 EBITDA stood at ₹103.68 Cr as against ₹ (14.50) Cr in Q1 FY26 with EBITDA Margin at 25.20% vs. (14.43%) in Q1 FY26. Margin trajectory reflects operating leverage on rising test-kit volumes, partly offset by continued investment in international go-to-market build-out
- Q1 FY27 PAT stood at ₹52.74 Cr as against ₹ (23.94) Cr in Q1 FY26, with PAT Margin at 12.82%.

Key Operating Metrics

KPIs	Q1 FY27	Q1 FY26	Q4 FY26
Truenat devices sold (Units)	164	216	1,158
Truenat test kits sold (Mn Units)	6.24	0.79	5.38
Domestic revenue mix (%)	*83.52%*	*81.84%*	*93.97%*
Export revenue mix (%)	*16.48%*	*18.16%*	*6.03%*

Management Commentary

Commenting on the performance, **Mr. Sriram Natarajan, Executive Director & Chief Executive Officer, Molbio Diagnostics Limited,** said:

"FY27 is a milestone year for Molbio, marking our transition to a listed company. I would like to thank our shareholders, employees, customers and partners for the trust they have placed in Molbio through our recent listing, and we remain committed to delivering on that trust through consistent execution. I am pleased to report that we have begun the year on a strong note, with healthy growth across both revenue and profitability in Q1. However, our business continues to have a non-linear revenue profile, with performance varying across quarters. We therefore believe it is important to assess our performance on a full-year basis. During the quarter, certain export orders pertaining to Q4 FY26, amounting to approximately ₹ 57 crore, were deferred due to the prevailing situation in the Gulf and were subsequently recognised in Q1 FY27. Total Income for Q1 FY27 stood at ₹411.48 Cr, with EBITDA at ₹103.68 Cr against a loss of ₹14.50 Cr in Q1 FY26. Growth continues to be led by test-kit consumption across the 12,500+ Truenat® devices sold in 90+ countries.

We entered FY27 with meaningful capacity headroom - FY26 device and test-kit utilisation at 42% and 58%, respectively, positioning us for volume-led scale-up without near-term incremental capex. Our pipeline of 34 additional assays across 22 diseases remains on track and will be a key long-term driver as we extend beyond infectious disease into oncology and other non-communicable areas.

Internationally, we are deepening our presence across Africa and Southeast Asia, entering Latin America, and progressing regulatory pathways in developed markets, including CE-IVDR for our CTNG Test.

Following our listing on August 17, 2026, deployment of the net issue proceeds is underway across capex for automation and building our R&D facility in Bengaluru. We remain focused on disciplined execution, sustained R&D intensity and improving cash flow quality as our international and acquired businesses scale."

About Molbio Diagnostics Limited

Molbio Diagnostics Limited (NSE: MOLBIO; BSE: 544866), is an innovative point-of-care diagnostics company headquartered in Goa, focused on expanding access to accurate, rapid and cost-effective diagnostic solutions for infectious and non-communicable diseases. Its flagship innovation, the Truenat® platform, is a novel, portable and battery-operated real-time PCR platform designed to enable decentralised molecular testing, including in resource-limited settings, with results available in about an hour. Protected by patents in more than 100 countries, Truenat® supports molecular testing for 30 diseases through 43 assays, including tuberculosis, COVID-19, Hepatitis B and C, HIV and HPV. Molbio's tuberculosis test is among only two rapid molecular diagnostic platforms globally endorsed by the World Health Organization (WHO) for the initial detection of tuberculosis and rifampicin resistance. As of March 31, 2026, more than 12,500 Truenat® devices have been installed in 90+ countries.

The Company has also expanded its product portfolio and entered areas including radiology, digital pathology and breast health screening through subsidiaries - Prognosys Medical Systems and OptraScan Inc. and strategic partnerships with UE Lifesciences.

For further information, please contact

Molbio Diagnostics Limited	Adfactors PR Pvt. Ltd.
Runjun Dutta Head – Communications runjun.dutta@molbiodiagnostics.com	**Janhavi Bellare** +91 93228 54508 janhavi.bellare@adfactorspr.com **Smit Shah/ Anand Venugopal** +91 9870789596 / +91 7021852071 smit.shah@adfactorspr.com anand.venugopal@adfactorspr.com